Table 1 Baseline information.
Selegiline | Rasagiline | Safinamide | |
|---|---|---|---|
Age in years (mean ± SD (n)) | 67.8 ± 12.7 (2667) | 70.0 ± 10.7 (7209) | 71.4 ± 9.8 (713) |
Number of combination drugsa (mean ± SD) | 8.5 ± 6.2 | 7.5 ± 5.6 | 7.8 ± 4.9 |
Monotherapyb (n, %) | 34 (0.8%) | 883 (8.3%) | 57 (5.6%) |
Female (n, %) | 1517 (42.6%) | 3998 (40.5%) | 415 (44.3%) |
Area (n, %) | |||
Northern America | 1523 (45.2%) | 6082 (59.6%) | 377 (40.4%) |
Western Europe | 201 (6.0%) | 1497 (14.7%) | 251 (26.9%) |
Eastern Asia | 991 (29.4%) | 708 (6.9%) | 29 (3.1%) |
Northern Europe | 310 (9.2%) | 799 (7.8%) | 62 (6.6%) |
Southern Europe | 231 (6.9%) | 439 (4.3%) | 197 (21.1%) |
Eastern Europe | 23 (0.7%) | 169 (1.7%) | 0 (0.0%) |
South America | 42 (1.2%) | 94 (0.9%) | 16 (1.7%) |
Western Asia | 4 (0.1%) | 130 (1.3%) | 0 (0.0%) |
Central America | 8 (0.2%) | 110 (1.1%) | 0 (0.0%) |
Australia and New Zealand | 22 (0.7%) | 90 (0.9%) | 1 (0.1%) |
Southern Asia | 5 (0.1%) | 40 (0.4%) | 1 (0.1%) |
South-eastern Asia | 11 (0.3%) | 19 (0.2%) | 0 (0.0%) |
Southern Africa | 0 (0.0%) | 19 (0.2%) | 0 (0.0%) |
Caribbean | 0 (0.0%) | 5 (0.0%) | 0 (0.0%) |
Northern Africa | 0 (0.0%) | 1 (0.0%) | 0 (0.0%) |
Micronesia | 0 (0.0%) | 1 (0.0%) | 0 (0.0%) |
